Colorectal

Blood In The Stool Could Point To More Than Colon Cancer

(NBC News) July 17, 2018 - People with blood in the stool are more likely to die of cancer, but also from other causes, researchers in Scotland report.

read article

By Sending Tests In The Mail, Researchers Boost Colorectal Cancer Screening

(UNC Lineberger CCC) July 13, 2018 - Researchers with UNC Lineberger’s Carolina Cancer Screening Initiative, in collaboration with the Mecklenburg County Health Department in Charlotte, examined the impact of targeted outreach to more than 2,100 people insured by Medicaid who were not up-to-date with colorectal cancer screening.

read article

Weight Loss Surgery May Affect the Risk of Cancer

(Wiley) July 16, 2018 - A new analysis published in the BJS (British Journal of Surgery) indicates that weight loss surgery may affect an individual’s risk of developing cancer.

read press release

Seattle Genetics Announces First Patient Dosed in Phase 2 innovaTV 207 Trial Evaluating Tisotumab Vedotin in Multiple Solid Tumors

(Seattle Genetics) July 12, 2018 - Seattle Genetics, Inc. today announced dosing of the first patient in the phase 2 innovaTV 207 clinical trial evaluating the activity, safety and tolerability of tisotumab vedotin as monotherapy in selected solid tumors with high Tissue Factor expression.

read corporate press release

Applying 'Already Done' Science to Cancer Control

(MedPage Today) July 11, 2018 - A fourth of cancer deaths in the U.S. would not occur if everyone had the same cancer mortality as college-educated Americans, authors of an American Cancer Society (ACS) study reported.

read article (free registration required)

Bristol-Myers Squibb’s Opdivo ® (nivolumab) + Low-Dose Yervoy ® (ipilimumab) is the First Immuno-Oncology Combination Approved for MSI-H/dMMR mCRC Patients Who Progressed Following Treatment with a Fluoropyrimidine, Oxaliplatin and Irinotecan

(BMS) July 11, 2018 - Bristol-Myers Squibb Company today announced Opdivo (nivolumab) 3 mg/kg plus low-dose Yervoy (ipilimumab) 1 mg/kg (injections for intravenous use) received approval from the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients 12 years and older with microsatellite instability high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin and irinotecan.

read corporate press release

Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

(NASDAQ) July 11, 2018 - Bavarian Nordic A/S today announced that the first patient has been dosed in a Phase 2 study evaluating the combination therapy of its cancer vaccine, CV301, and Bristol Myers Squibb's checkpoint inhibitor, nivolumab (OPDIVO®), for the treatment of patients with resectable hepatic-limited metastatic colorectal cancer (mCRC).

read article

Researchers Apply Computing Power To Track The Spread Of Cancer

(Princeton University) June 29, 2018 - Princeton researchers have developed a new computational method that increases the ability to track the spread of cancer cells from one part of the body to another.

read article

Immunotherapy Disappoints in Metastatic Colorectal Cancer

(Medscape Medical News) June 27, 2018 - Hope that arose from an earlier trial turned into disappointment with the results of the IMblaze370 phase 3 study, conducted in patients with metastatic colorectal cancer (mCRC) who experienced disease progression while taking chemotherapy.

read article (free registration required)

FDA to Release List of Surrogate Endpoints in Oncology

(Regulatory Focus) June 25, 2018 - Scott Gottlieb, FDA Commissioner, said Monday at the National Press Club in Washington, DC that his agency will release a list of surrogate endpoints used in cancer drug development soon.

read article

Research Team Discovers Drug Compound that Stops Cancer Cells from Spreading

(The Lund Report [Portland, OR]) June 22, 2018 - New research, published today in the journal Nature Communications, shows that it may be possible to freeze cancer cells and kill them where they stand.

read article

Taiho and Servier Present Promising Data on LONSURF® (trifluridine and tipiracil) at ESMO 20th World Congress on Gastrointestinal Cancer 2018

(Taiho Pharma) June 25, 2018 - Taiho Pharmaceutical Co., Ltd. and Servier announced that promising clinical data for LONSURF® (trifluridine and tipiracil) from the pivotal Phase III TAGS trial and Phase II TASCO-1 trial were presented at the ESMO 20th World Congress on Gastrointestinal Cancer 2018 (ESMO-GI) in Barcelona, Spain, June 20 to 23.

read corporate press release

Do Frequent Follow-Up Tests Benefit Colorectal Cancer Survivors?

(NCI/Cancer Currents Blog) June 20, 2018 - Undergoing follow-up testing for cancer recurrence more than once a year may not benefit people who have been treated for colorectal cancer, results from two new studies show.

read article

Research Shows That Diet Can Lower Risk Of Recurrence In Stage III Colon Cancer

(Dana-Farber) June 21, 2018 - New research led by Dana-Farber Cancer Institute investigators suggests that patients treated for non-metastatic colon cancer may sharply reduce the risk that the disease will return by following a diet low in carbohydrates and other foods that raise insulin levels.

read press release

ASCO 2018: Large Study of DNA Mismatch Repair Genes Determines Mutation Frequency in Several Types of Cancer

(ESMO) June 20, 2018 - Results from a study evaluating the relationship between the number of somatic mutations (SMs) in four mismatch repair (MMR) genes and the microsatellite instability (MSI) phenotype showed specific mutations in DNA repair genes associated with younger age, and specific cancer types.

read article

New Study in JNCCN Raises Questions about Resource Availability at Hospitals on Weekends and Holidays

(NCCN) June 21, 2018 - The likelihood of severe complications after emergency colon cancer surgery is significantly higher over the weekend, according to a new study in the latest issue of JNCCN – Journal of the National Comprehensive Cancer Network.

read press release

Exploring a New Treatment for Metastatic Colorectal Cancer

(Rutgers/CINJ) June 19, 2018 - Rutgers Cancer Institute of New Jersey is offering a clinical trial targeting an advanced form of colorectal cancer with a combination vaccine/immunotherapy drug treatment.

read press release

Latecomer Sanofi Looks To Catch Next Wave Of Cancer Therapies

(Reuters) June 20, 2018 - Sanofi missed the boat on immune system-boosting cancer drugs. Now it’s trying to catch up.

read article

Taiho Oncology and Servier to Present Data on LONSURF® (trifluridine and tipiracil) and Key Investigational Compound TAS-120 at ESMO 20th World Congress on Gastrointestinal Cancer 2018

(Morningstar) June 14, 2018 - Taiho Oncology, Inc. and Servier today announced that clinical data for LONSURF® (trifluridine and tipiracil, TAS-102) are being presented at the ESMO 20th World Congress on Gastrointestinal Cancer 2018 (ESMO-GI) in Barcelona, Spain, June 20 to 23.

read article

Higher Vitamin D Levels Linked To Lower Colorectal Cancer Risk, Study Finds

(Washinton Post/To Your Health) June 14, 2018 - Higher concentrations of vitamin D circulating in the bloodstream are linked to a lower risk of colorectal cancer, according to a large international study published Thursday.

read article (free registration required)
Next Page